Last reviewed · How we verify
Standard-dose rivaroxaban
Standard-dose rivaroxaban, marketed by the China National Center for Cardiovascular Diseases, holds a significant position in the cardiovascular disease treatment market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. However, the primary risk lies in potential competition from generic versions post-patent expiry.
At a glance
| Generic name | Standard-dose rivaroxaban |
|---|---|
| Sponsor | China National Center for Cardiovascular Diseases |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis (PHASE4)
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing (PHASE3)
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma (NA)
- Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (PHASE3)
- inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: